Login to Your Account



'12 Plus 12' Beats Standard Of Care

Vertex Offers Interim Results From Phase IIb Trials In HCV

By Randall Osborne


Monday, November 5, 2007
Wall Street nicked shares of Vertex Pharmaceuticals Inc. on word of results from two Phase IIb trials with its protease inhibitor telaprevir, as investors apparently were turned off by somewhat lower than expected sustained viral response (SVR), though the drug beat standard of care. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription